A 3-part Study of ABCI: a Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Phase 1a Study in Healthy Volunteers (Part A), a Randomized, Double-blind, Placebo-controlled, 14- and 28-day Multiple-ascending Dose Phase 1a Study in Healthy Volunteers (Part B), and a 28-day Open-Label Phase 1b Study in Subjects with Cystic Fibrosis (Part C)
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Amphotericin B inhalation (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms ABCI
- Sponsors cystetic Medicines
Most Recent Events
- 12 Feb 2025 Planned number of patients changed from 84 to 108.
- 12 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 12 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.